Michael C. Donegan - Jan 26, 2023 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
Prin. Fin. and Acctg. Officer
Signature
/s/ Michael C. Donegan
Stock symbol
TXMD
Transactions as of
Jan 26, 2023
Transactions value $
-$8,621
Form type
4
Date filed
1/30/2023, 05:40 PM
Previous filing
Jan 25, 2023
Next filing
Feb 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise $0 +2.4K +31.54% $0.00 10K Jan 26, 2023 Direct F1
transaction TXMD Common Stock Options Exercise $0 +2.4K +23.98% $0.00 12.4K Jan 26, 2023 Direct F1
transaction TXMD Common Stock Options Exercise $0 +1.14K +9.19% $0.00 13.6K Jan 26, 2023 Direct F1
transaction TXMD Common Stock Sale -$8.37K -1.65K -12.16% $5.08 11.9K Jan 26, 2023 Direct F2, F3
transaction TXMD Common Stock Sale -$249 -49 -0.41% $5.09 11.9K Jan 27, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Performance Stock Units Options Exercise $0 -2.4K -100% $0.00* 0 Jan 26, 2023 Common Stock 2.4K $0.00 Direct F1, F4
transaction TXMD Performance Stock Units Options Exercise $0 -2.4K -100% $0.00* 0 Jan 26, 2023 Common Stock 2.4K $0.00 Direct F1, F4
transaction TXMD Performance Stock Units Options Exercise $0 -1.14K -100% $0.00* 0 Jan 26, 2023 Common Stock 1.14K $0.00 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).
F2 The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4 Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".